Rheumatoid Arthritis DMARD Intervention and UtilizationStudy

Rheumatoid Arthritis Disease Modifying Anti-Rheumatic Drug (DMARD) Intervention and Utilization Study (RADIUS 2)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00116727

Enrollment

5103

Registered

2005-07-01

Start date

2002-10-31

Completion date

2008-10-31

Last updated

2011-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

Rheumatoid Arthritis, DMARD

Brief summary

To systematically collect and document use patterns, effectiveness and safety of DMARD treatments currently used in the management of rheumatoid arthritis. The primary purpose of this study is to estimate the incidence of serious adverse experiences and adverse experiences of interest in patients with rheumatoid arthritis (RA) treated with ENBREL®.

Interventions

DRUGENBREL®

50 mg/wk SC

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Fulfillment of the 1987 American Rheumatism Association criteria for RA * Currently requiring the addition of ENBREL® therapy (to be taken alone or in addition to their current DMARD therapy)

Exclusion criteria

* Currently or previously enrolled in RADIUS 1 * Currently enrolled in a clinical trial where treatments or patient visits are imposed by a protocol * Active infections * Known allergy to ENBREL® or any of its components * Current treatment with ENBREL® * Patients who have previously been demonstrated to be intolerant of or refractory to ENBREL® therapy * Nursing or pregnant women

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 30, 2026